ARCT
Arcturus Therapeutics Holdings Inc.
Biotechnology
Market Cap$260M
5Y Perf.-77.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ARCT vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$175.76B
5Y Perf.+37.2%
ARCT vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ARCT | TMO |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $260M | $175.76B |
| Revenue (TTM) | $74M | $45.20B |
| Net Income (TTM) | $-66M | $6.86B |
| Gross Margin | 94.6% | 39.4% |
| Operating Margin | -101.1% | 17.8% |
| Forward P/E | — | 19.0x |
| Total Debt | $25M | $40.85B |
| Cash & Equiv. | $231M | $9.86B |
ARCT vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ARCT
TMO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Arcturus Therapeuti… (ARCT) | 100 | 22.9 | -77.1% |
| Thermo Fisher Scien… (TMO) | 100 | 137.2 | +37.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARCT vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 6 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
ARCT
Arcturus Therapeutics Holdings Inc.
The Defensive Pick
ARCT is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 2.41, Low D/E 11.7%, current ratio 6.64x
Best for: sleep-well-at-night
TMO
Thermo Fisher Scientific Inc.
The Income Pick
TMO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 8 yrs, beta 1.10, yield 0.4%
- Rev growth 3.9%, EPS growth 7.3%, 3Y rev CAGR -0.3%
- 229.1% 10Y total return vs ARCT's -68.6%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TMO | 3.9% revenue growth vs ARCT's -51.4% |
| Quality / Margins | TMO | 15.2% margin vs ARCT's -88.7% |
| Stability / Safety | TMO | Beta 1.10 vs ARCT's 2.41 |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | TMO | +16.6% vs ARCT's -18.8% |
| Efficiency (ROA) | TMO | 6.4% ROA vs ARCT's -22.0%, ROIC 7.5% vs -277.1% |
ARCT vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
ARCT vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTMOLAGGINGARCT
ARCTArcturus Therapeutics…
1leads
TMOThermo Fisher Scienti…
4leads
6 Total Categories
CATEGORYLEADERvs ARCTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TMO5/6
Valuation MetricsMultiples, price ratios, and targets
ARCT3/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TMO5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
TMO5/6
Risk & VolatilityBeta, volatility, and downside exposure
TMO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TMO leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 609.7x ARCT's $74M. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to ARCT's -88.7%. On growth, TMO holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ARCTArcturus Therapeu… | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $74M | $45.2B |
| EBITDAEarnings before interest/tax | -$72M | $10.5B |
| Net IncomeAfter-tax profit | -$66M | $6.9B |
| Free Cash FlowCash after capex | -$75M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +94.6% | +39.4% |
| Operating MarginEBIT ÷ Revenue | -101.1% | +17.8% |
| Net MarginNet income ÷ Revenue | -88.7% | +15.2% |
| FCF MarginFCF ÷ Revenue | -100.8% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -85.3% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +5.4% | +11.3% |
TMO leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
ARCT leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ARCTArcturus Therapeu… | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $260M | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $54M | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | -3.80x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.62x |
| EV / EBITDAEnterprise value multiple | — | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 3.86x | 3.94x |
| Price / BookPrice ÷ Book value/share | 1.17x | 3.33x |
| Price / FCFMarket cap ÷ FCF | — | 27.93x |
ARCT leads this category, winning 3 of 3 comparable metrics.
Profitability & Efficiency
TMO leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-29 for ARCT. ARCT carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), TMO scores 6/9 vs ARCT's 1/9, reflecting solid financial health.
| Metric | ARCTArcturus Therapeu… | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | -29.1% | +13.2% |
| ROA (TTM)Return on assets | -22.0% | +6.4% |
| ROICReturn on invested capital | -2.8% | +7.5% |
| ROCEReturn on capital employed | -29.2% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 6 |
| Debt / EquityFinancial leverage | 0.12x | 0.76x |
| Net DebtTotal debt minus cash | -$206M | $31.0B |
| Cash & Equiv.Liquid assets | $231M | $9.9B |
| Total DebtShort + long-term debt | $25M | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | — | 5.89x |
TMO leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
TMO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $3,028 for ARCT. Over the past 12 months, TMO leads with a +16.6% total return vs ARCT's -18.8%. The 3-year compound annual growth rate (CAGR) favors TMO at -4.2% vs ARCT's -31.6% — a key indicator of consistent wealth creation.
| Metric | ARCTArcturus Therapeu… | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | +46.1% | -20.1% |
| 1-Year ReturnPast 12 months | -18.8% | +16.6% |
| 3-Year ReturnCumulative with dividends | -68.0% | -11.9% |
| 5-Year ReturnCumulative with dividends | -69.7% | +2.1% |
| 10-Year ReturnCumulative with dividends | -68.6% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -31.6% | -4.2% |
TMO leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
TMO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TMO is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than ARCT's 2.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TMO currently trades 73.4% from its 52-week high vs ARCT's 37.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARCTArcturus Therapeu… | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.41x | 1.10x |
| 52-Week HighHighest price in past year | $24.17 | $643.99 |
| 52-Week LowLowest price in past year | $5.85 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +37.8% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 453K | 1.9M |
TMO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ARCT as "Buy" and TMO as "Buy". Consensus price targets imply 146.4% upside for ARCT (target: $23) vs 38.4% for TMO (target: $655). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | ARCTArcturus Therapeu… | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $22.50 | $654.67 |
| # AnalystsCovering analysts | 21 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
Insufficient data to determine a leader in this category.
Key Takeaway
TMO leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARCT leads in 1 (Valuation Metrics).
Best OverallThermo Fisher Scientific In… (TMO)Leads 4 of 6 categories
Loading custom metrics...
ARCT vs TMO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is ARCT or TMO a better buy right now?
For growth investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Arcturus Therapeutics Holdings Inc. (ARCT) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARCT or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 1%, compared to -69. 7% for Arcturus Therapeutics Holdings Inc. (ARCT). Over 10 years, the gap is even starker: TMO returned +229. 1% versus ARCT's -69. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARCT or TMO?
By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.
(TMO) is the lower-risk stock at 1. 10β versus Arcturus Therapeutics Holdings Inc. 's 2. 41β — meaning ARCT is approximately 120% more volatile than TMO relative to the S&P 500. On balance sheet safety, Arcturus Therapeutics Holdings Inc. (ARCT) carries a lower debt/equity ratio of 12% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ARCT or TMO?
By revenue growth (latest reported year), Thermo Fisher Scientific Inc.
(TMO) is pulling ahead at 3. 9% versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). On earnings-per-share growth, the picture is similar: Arcturus Therapeutics Holdings Inc. grew EPS 20. 0% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Over a 3-year CAGR, TMO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ARCT or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus -97. 9% for Arcturus Therapeutics Holdings Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -111. 5% for ARCT. At the gross margin level — before operating expenses — ARCT leads at 95. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ARCT or TMO more undervalued right now?
Analyst consensus price targets imply the most upside for ARCT: 146.
4% to $22. 50.
07Which pays a better dividend — ARCT or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. ARCT does not pay a meaningful dividend and should not be held primarily for income.
08Is ARCT or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). Arcturus Therapeutics Holdings Inc. (ARCT) carries a higher beta of 2. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMO: +229. 1%, ARCT: -69. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ARCT and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ARCT: -85.3% · TMO: 6.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.